Show simple item record

dc.contributor.authorBroadley, Simon A
dc.contributor.authorBarnett, Michael H
dc.contributor.authorBoggild, Mike
dc.contributor.authorBrew, Bruce J
dc.contributor.authorButzkueven, Helmut
dc.contributor.authorHeard, Robert
dc.contributor.authorHodgkinson, Suzanne
dc.contributor.authorKermode, Allan G
dc.contributor.authorLechner-Scott, Jeannette
dc.contributor.authorMacdonell, Richard AL
dc.contributor.authorMarriott, Mark
dc.contributor.authorMason, Deborah F
dc.contributor.authorParratt, John
dc.contributor.authorReddel, Stephen W
dc.contributor.authorShaw, Cameron P
dc.contributor.authorSlee, Mark
dc.contributor.authorSpies, Judith M
dc.contributor.authorTaylor, Bruce V
dc.contributor.authorCarroll, William M
dc.contributor.authorKilpatrick, Trevor J
dc.contributor.authorKing, John
dc.contributor.authorMcCombe, Pamela A
dc.contributor.authorPollard, John D
dc.contributor.authorWilloughby, Ernest
dc.date.accessioned2018-07-26T12:30:32Z
dc.date.available2018-07-26T12:30:32Z
dc.date.issued2015
dc.identifier.issn0025-729X
dc.identifier.doi10.5694/mja14.01218
dc.identifier.urihttp://hdl.handle.net/10072/141918
dc.description.abstract- Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history. - A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease. While a cure for MS remains elusive, the potential to reduce inflammatory disease activity by preventing relapses and minimising disease progression is achievable. - The importance of early treatment in minimising long-term disability is increasingly recognised. Most of the newer, more effective therapies are associated with risks and practical problems that necessitate an active management strategy and continuous vigilance. - While the initiation of these therapies is likely to remain the responsibility of neurologists, other specialist physicians and general practitioners will be involved in the identification and management of adverse effects.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherAustralasian Medical Publishing Company
dc.relation.ispartofpagefrom139
dc.relation.ispartofpageto141
dc.relation.ispartofissue3
dc.relation.ispartofjournalThe Medical Journal of Australia
dc.relation.ispartofvolume203
dc.subject.fieldofresearchClinical Sciences not elsewhere classified
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchPsychology
dc.subject.fieldofresearchcode110399
dc.subject.fieldofresearchcode1117
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1701
dc.titleA new era in the treatment of multiple sclerosis
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dc.description.versionPublished
gro.facultyGriffith Health, School of Medicine
gro.rights.copyrightBroadley SA, Barnett MH, Boggild M, et al. A new era in the treatment of multiple sclerosis. Med J Aust 2015; 203 (3): 139-141. © Copyright 2015 The Medical Journal of Australia – reproduced with permission.
gro.hasfulltextFull Text
gro.griffith.authorBroadley, Simon
gro.griffith.authorButzkueven, Helmut


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record